Investigator

Dylan M. Glubb

Research Officer · QIMR Berghofer Medical Research Institute, Genetics and Computational Biology

DMGDylan M. Glubb
Papers(2)
Dietary Factors and E…Identification of a L…
Collaborators(10)
Florian HeitzFrancesmary ModugnoIgnace VergoteJue-Sheng OngJulie M. CunninghamMatthias DürstMichael C.J. QuinnMichael FriedlanderPaul D P PharoahPeter A. Fasching
Institutions(9)
Qimr Berghofer Medica…Kliniken Essen-Mitte …University Of Pittsbu…European UnionMayo ClinicUniversitätsklinikum …Prince of Wales Hospi…Cedars-Sinai Medical …Universittsklinikum E…

Papers

Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer

Abstract Background: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance. Methods: We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy. Results: We found seven SNPs at 12q24.33 associated with PFS (P < 5 × 10–8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15–1.34; P = 1.47 × 10–8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro. Conclusions: The locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association. Impact: This finding provides insight into genetic markers associated with EOC outcome and potential treatment options. See related commentary by Peres and Monteiro, p. 1604

56Works
2Papers
27Collaborators

Positions

2013–

Research Officer

QIMR Berghofer Medical Research Institute · Genetics and Computational Biology

2011–

Postdoctoral Research Associate

University of North Carolina at Chapel Hill · Institute of Pharmacogenomics and Individualized Therapy

2009–

Postdoctoral Scholar

University of Chicago · Medicine

2008–

Research Fellow

University of Otago Christchurch · Pathology

Education

2009

PhD

University of Otago Christchurch · Pathology

Country

AU

Keywords
Cancer geneticsEndometrial cancerBreast cancerOvarian cancerFunctional geneticsGWAS follow-upEpigenomics
Links & IDs
0000-0002-2184-7708QIMR Berghofer personal pageGoogle Scholar page

Scopus: 23970679000

Researcher Id: M-7514-2016